title: Prevalence of advanced bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma.
abstract: In the last decade, 13-cis-retinoic acid (13-cis-RA) has been added to the treatment of patients with high-risk neuroblastoma. In survivors of neuroblastoma, short stature is consistently observed. Causes include growth hormone deficiency and poor growth of irradiated long bones. Within the survivorship program at CHOP, we have observed that a number of these patients also have advanced bone ages. Children treated with 13-cis-RA are at risk for advanced bone age that may dramatically impact their linear growth. Ongoing evaluation is necessary to examine the effect of 13-cis-RA on final adult height and to inform clinical practice in this cohort.
authors.affiliation: Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.
authors.forename: Wendy L
authors.initials: WL
authors.lastname: Hobbie
authors.forename: Sogol Moab
authors.initials: SM
authors.lastname: Mostoufi
authors.forename: Sogol Mostoufi
authors.initials: SM
authors.lastname: Moab
authors.forename: Claire A
authors.initials: CA
authors.lastname: Carlson
authors.forename: Denise
authors.initials: D
authors.lastname: Gruccio
authors.forename: Jill P
authors.initials: JP
authors.lastname: Ginsberg
mesh_terms: D000365:Age Determination by Skeleton; D001827:Body Height / Q000187:drug effects*; D015519:Bone Density / Q000187:drug effects*; D001848:Bone Diseases, Developmental / Q000473:pathology; D016026:Bone Marrow Transplantation; D002675:Child, Preschool; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003879:Dermatologic Agents / Q000009:adverse effects; D005260:Female; D006128:Growth / Q000187:drug effects*; D006130:Growth Disorders / Q000473:pathology*; D006801:Humans; D007223:Infant; D015474:Isotretinoin / Q000009:adverse effects*; D008297:Male; D009447:Neuroblastoma / Q000473:pathology / Q000628:therapy*; D015995:Prevalence; D011829:Radiation Dosage; D012189:Retrospective Studies; D017741:Survivors; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D015474:Isotretinoin